AI English summary of an SEC filing — figures as filed
Zimmer Biomet ZBHThe company said net sales for Q3 2024 were $1.824 billion, up 4.0% from the prior-year period, and up 4.1% on a constant currency basis.
Key points
AI summaryThe company said net sales for Q3 2024 were $1.824 billion, up 4.0% from the prior-year period, and up 4.1% on a constant currency basis.
Zimmer Biomet said its net earnings attributable to the company for Q3 2024 were $249.1 million, with diluted earnings per share of $1.23. On an adjusted basis, net earnings were $353.2 million and diluted earnings per share were $1.74.
Zimmer Biomet said it reduced and narrowed its full-year 2024 outlook, cutting the reported revenue change range to 3.5% to 4.0% from the prior 4.0% to 5.0% and lowering adjusted diluted EPS to $7.95 to $8.05 from $8.00 to $8.15.
The company said operating cash flow was $993.1 million and free cash flow was $652.4 million for the 9 months ended September 30, 2024, and that it spent $795.8 million on share repurchases.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
Q3 2024 Net Sales $1.824 billion
The company said net sales for Q3 2024 were $1.824 billion, up 4.0% from the prior-year period, and up 4.1% on a constant currency basis.
Source · Based on the filing body and exhibits
Q3 Net Earnings and Earnings Per Share
Zimmer Biomet said its net earnings attributable to the company for Q3 2024 were $249.1 million, with diluted earnings per share of $1.23. On an adjusted basis, net earnings were $353.2 million and diluted earnings per share were $1.74.
Source · Based on the filing body and exhibits
Full-Year Outlook Cut and Narrowed
Zimmer Biomet said it reduced and narrowed its full-year 2024 outlook, cutting the reported revenue change range to 3.5% to 4.0% from the prior 4.0% to 5.0% and lowering adjusted diluted EPS to $7.95 to $8.05 from $8.00 to $8.15.
Source · Based on the filing body and exhibits
9-Month Share Repurchases and Free Cash Flow
The company said operating cash flow was $993.1 million and free cash flow was $652.4 million for the 9 months ended September 30, 2024, and that it spent $795.8 million on share repurchases.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…